Tirzepatide vs Semaglutide: The Practical Differences That Matter When You Research Weight Loss

What the head-to-head evidence shows (and what it does not)

SURMOUNT-5 is the trial most people mean when they ask whether tirzepatide beats semaglutide for weight loss. It compared the two drugs directly in adults with obesity and was published in the New England Journal of Medicine in 2025. In the published results, average weight reduction at 72 weeks was roughly 20 percent with tirzepatide and roughly 14 percent with semaglutide. Read the paper itself for exact figures, population details, and endpoint definitions, because summaries often blur the difference between treatment-regimen and on-treatment analyses.

SURPASS-2 asked a different question. It compared the same two drugs in adults with type 2 diabetes, and its primary endpoint was change in HbA1c, a measure of average blood sugar over roughly three months. Weight was tracked as a secondary outcome. Tirzepatide lowered HbA1c more than semaglutide in that study, so it tells you more about glycemic control than about how much fat someone with obesity will lose.

Head-to-head data still has limits. SURMOUNT-5 was open-label, which means participants and clinicians knew which drug was being given. That can shape dose adjustments, how side effects get recorded, and how people behave. The trial was also sponsored by the company that makes tirzepatide. That's a standard disclosure, not an accusation, but it's worth knowing. Populations differ too. Diabetes and obesity trials enroll different people, with different baseline weights, medications, and metabolic profiles.

Older placebo-controlled trials such as STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) are useful, but their numbers can't be lined up neatly against SURMOUNT-5. Different durations, dose ranges, and enrollment criteria make cross-trial comparisons fragile. So is tirzepatide better than semaglutide for weight loss? In one well-designed head-to-head trial, average weight loss was larger with tirzepatide. That's a meaningful finding, but a single trial in a specific population doesn't settle what will happen to you.

Dosing, titration, and the weekly schedule

Both drugs start low and climb slowly, but the steps are not the same. For Wegovy, the semaglutide product approved for weight management, the label begins at 0.25 mg once weekly and increases in steps of roughly four weeks or more toward a maintenance dose of 2.4 mg. Zepbound, the tirzepatide product for weight management, starts at 2.5 mg weekly and increases in 2.5 mg steps, with at least four weeks at each level, up to a maximum of 15 mg. Don't assume a dose number means the same thing across products.

The slow titration gives your gut time to adjust and lowers the chance of side effects that show up when the dose jumps too fast. The labels also allow some flexibility. Your prescriber may keep you at a dose longer if you aren't tolerating the next step. Whether and how that happens depends on the product and your situation, so raise it with your prescriber rather than changing doses on your own.

Missed doses are where people most often get tripped up. The two products do not use the same window. At the time of writing, the US labels allow a late Wegovy dose up to five days after the scheduled day, while Zepbound's window is four days. After that, you skip the missed dose and resume on your usual day. Labels get revised, so confirm the current window in the prescribing information you actually have.

Storage matters just as much. Before first use, both products are kept refrigerated and must not be frozen. After first use, each has its own room-temperature allowance, measured in weeks, and the two labels don't match. If a pen was left out longer than the label permits, or you aren't sure how long it sat, don't guess. Call the pharmacy and ask. Dosing and storage details change, so check your own prescribing information and treat this section as a general guide only.

Side effect profiles compared

Gastrointestinal events were the most common adverse events in the main trials of both drugs. Nausea and constipation have their own deeper coverage elsewhere, so here the focus is on what differs and what needs a clinician's attention. PeptPro writes plain-language material on dosing and tolerability, and its PeptPro's dosing and tolerability guides are a practical companion when you compare label details side by side.

Both drugs carry a boxed warning about thyroid C-cell tumors, which were seen in rodent studies. The warning exists because rodent findings can't be automatically assumed to apply to humans, and the labels take a cautious approach. Both products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). If that applies to you or your family, these drugs are not an option, and your prescriber needs your full family history before you start.

Hypoglycemia depends heavily on context. Risk rises when these drugs are combined with insulin or sulfonylureas, which is why it matters more in diabetes care. In weight-focused use without those medications, the risk is lower, though not zero, especially if food intake drops sharply. Ask your prescriber how they would adjust any diabetes medicines you already take.

Both labels also include warnings about gallbladder events and pancreatitis. These are reported risks, not reasons to panic. They are worth discussing with a clinician, particularly if you have a history of gallstones or pancreatic problems. Severe abdominal pain that doesn't go away, especially with vomiting, needs urgent medical attention rather than a wait-and-see approach.

The practical differences people actually run into

Cost and coverage often decide which drug people end up on. Insurance formularies differ by plan and by country, and a product covered by one plan may be excluded by another. Check your own formulary and ask your prescriber which drug your plan is likely to cover. Prices change, so this post doesn't quote any.

Availability has also shifted. Both semaglutide and tirzepatide have appeared on shortage lists at different points, and the status of each can change. The FDA maintains a public drug shortage database, and other regulators publish their own listings. Check before you plan refills or travel, and expect supply to fluctuate.

Pen formats affect your routine more than people expect. Products differ in how many doses each pack holds, the dose increments each pen delivers, and how the pen is handled between doses. Those details shape how you plan refills, how much you carry when traveling, and how you handle a dose change. Read the presentation section of the label for your exact product.

Interactions deserve a conversation with your prescriber. Because these drugs slow stomach emptying, they can change how quickly oral medicines are absorbed. The labels describe specific interactions, including one relevant to some oral hormonal contraceptives. Tell your prescriber about every medication, supplement, and over-the-counter product you use. Be cautious with compounded or unregulated versions too, since regulators have warned about them.

Where the evidence is still thin, and what to ask before starting or switching

Long-term outcome data is the biggest gap. The SELECT trial studied semaglutide in adults with overweight or obesity and established cardiovascular disease, and it reported a reduction in major cardiovascular events. Tirzepatide's dedicated cardiovascular outcome trial, SURMOUNT-MMO, was still listed as ongoing when this post was written, so check its registry entry before drawing conclusions.

Weight regain after stopping is another area to read closely. Discontinuation analyses report this differently depending on trial design and follow-up length, so look for the figures in the source papers rather than relying on secondhand summaries. Don't assume the pattern carries over from one drug to the other.

Lean tissue deserves attention too. Weight loss of any kind can include muscle as well as fat, and that's a good reason to ask whether your clinician wants you to track protein intake or add resistance training during treatment. A dietitian can help turn that into a realistic routine.

When you sit down with a prescriber, bring specific questions. PeptPro also covers how to prepare for these visits, and the PeptPro notes on questions to ask a prescriber can help you organize what you want to raise. Start with three:

• Which of these drugs fits my health history, including thyroid, pancreatic, and family history?
• What monitoring do you recommend, and how often should we review it?
• Under what circumstances would you switch me to the other drug?

No drug guarantees a specific result, and the right choice depends on your body, your history, and what your plan covers. Use the trial data to sharpen your questions, then let your prescriber help you decide. Tirzepatide and semaglutide may help some people lose weight, and they are studied in many settings, but they are not cures and they are not a shortcut around medical oversight.

FAQ

Is tirzepatide better than semaglutide for weight loss?

In the SURMOUNT-5 head-to-head trial, average weight loss was larger with tirzepatide than with semaglutide. One trial in one population doesn't guarantee the same result for everyone, so the better fit depends on your health history and your prescriber's judgment.

Are tirzepatide and semaglutide the same type of medicine?

They belong to the same broad incretin family and both are injected weekly, but they act on different receptors. Semaglutide targets GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors.

What happens if I miss a dose?

The label windows differ between the two products. Check the prescribing information for the exact product you have, and ask your pharmacist or prescriber if you're unsure whether to take a late dose or skip it.

Can I get these without a prescription?

In most countries, both are prescription medicines. Buying from unregulated sources carries real risks, including products that aren't what they claim to be, so talk to a licensed prescriber first.

Sources

• SURMOUNT-5: Tirzepatide versus Semaglutide for Obesity, New England Journal of Medicine (2025)
• SURPASS-2: Tirzepatide versus Semaglutide in Type 2 Diabetes, New England Journal of Medicine (2021)
• SELECT: Semaglutide and Cardiovascular Outcomes in Obesity, New England Journal of Medicine (2023)
• ClinicalTrials.gov: SURMOUNT-MMO (NCT05556512)
• Drugs@FDA: Wegovy (semaglutide) prescribing information, NDA 215256
• Drugs@FDA: Zepbound (tirzepatide) prescribing information, NDA 217806
• FDA Drug Shortages Database